Frequency and Use of Medications in Horses Racing at Prairie Meadows

An analysis was made of the horses racing at Prairie Meadows race track in Altoona, Iowa during 1993 to determine the number of entries designated as racing under the influence of phenylbutazone (Bute(RX)), furosemide (Lasix(Rx)) or both medications. In a total of 1379 Quarter Horse entries, 5.7 % raced with no medication, 74.9 % raced on phenylbutazone, 0.5 % raced on furosemide, and 18.9 % raced on both phenylbutazone and furosemide. In a total of 3424 Thoroughbred entries, 2.1 % raced under no medication, 43.6 % raced on phenylbutazone, 0.4 % raced on furosemide, and 53.9 % raced on both phenylbutazone and furosemide. Overall, of the 4803 entries, 3.2 % raced with no medication, 52.6 % raced on phenylbutazone, 0.4 % raced on furosemide, and 43.9 % raced on both phenylbutazone and furosemide

The Effect of Furosemide on Arterial Blood Gases and Performance in Quarter Horses Performing a Fatigue Test on a Treadmill

Four Quarter Horses (1 filly age 2, 1 mare age 5 and 2 geldings ages 3 and 4; average weight 539 kg) were used in a 2 x 2 crossover design. The effects of furosemide (Lasix(Rx)) on arterial blood packed ceii voiume (PCV), hemogiobin (Hb), pH, pO2, pCO2, HCO-3 and base excess (BE) were measured. Plasma lactate, heart rate, and fatigue time were determined as indicators of perlormance while the horses performed a fatigue test on a high-speed treadmill. The left carotid artery was surgically elevated subcutaneously to facilitate collection of arterial blood samples. Horses were conditioned for 13 weeks with increasing intensity then randomly assigned furosemide (F) or physiological saline (C) as treatments. Treatments were administered 4 hours prior to the fatigue test in accordance with racing regulations. Arterial blood samples were collected prior to treatment dose, prior to exercise, at the 2nd, 4th, and 6th minute during the fatigue test, at fatigue, and at the 5th, 15th, 30th, and 45th minute post-exercise. Arterial blood samples were analyzed for blood gases, Hb, PCV, and plasma lactate. Heart rate and fatigue time were recorded. No difference between treatments (P \u3e 0.05) was observed for blood gases except for pCO2 at rest, and HCO-3 and BE at the 2 minute collection period. No difference between treatments (P \u3e 0.05) was observed for Hb, PCV, lactate and heart rate except at 15 minutes post-exercise for Hb and PCV, and 45 minutes postexercise for Hb. Fatigue times were 11 min 56 sec ± 5 min 30 sec for F horses and 11 min 35 sec--± 2 min 6 sec for C horses. No difference (P \u3e 0.05) was observed in fatigue time. Based on our data, the trend indicated that all parameters measured returned to pre-exercise levels more rapidly for furosemide treated horses. However, furosemide did not enhance performance

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

Abstract Background BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Results Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10−5) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor–positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15–21.80] and progesterone receptor–positive (OR 5.04; 95 % CI 3.17–8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10−12). Conclusions On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

Abstract Background BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Results Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10−5) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor–positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15–21.80] and progesterone receptor–positive (OR 5.04; 95 % CI 3.17–8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10−12). Conclusions On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management